Literature DB >> 24940651

Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.

Brittany G Craiglow1, Brett A King2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24940651     DOI： 10.1038/jid.2014.260

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  10 in total

1.  Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis?

Authors:  R Rückert; K Asadullah; M Seifert; V M Budagian; R Arnold; C Trombotto; R Paus; S Bulfone-Paus
Journal:  J Immunol       Date:  2000-08-15       Impact factor: 5.422

2.  Treatment of alopecia areata by anthralin-induced dermatitis.

Authors:  C Schmoeckel; I Weissmann; G Plewig; O Braun-Falco
Journal:  Arch Dermatol       Date:  1979-10

3.  Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis.

Authors:  Mary G Boy; Cunshan Wang; Bethanie E Wilkinson; Vincent Fung-Sing Chow; Alan T Clucas; James G Krueger; Anderson S Gaweco; Samuel H Zwillich; Paul S Changelian; Gary Chan
Journal:  J Invest Dermatol       Date:  2009-02-19       Impact factor: 8.551

4.  Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.

Authors:  C Mamolo; J Harness; H Tan; A Menter
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-01-07       Impact factor: 6.166

Review 5.  Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.

Authors:  Marko Pesu; Fabio Candotti; Matthew Husa; Sigrun R Hofmann; Luigi D Notarangelo; John J O'Shea
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

6.  Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.

Authors:  B Strober; M Buonanno; J D Clark; T Kawabata; H Tan; R Wolk; H Valdez; R G Langley; J Harness; A Menter; K Papp
Journal:  Br J Dermatol       Date:  2013-11       Impact factor: 9.302

7.  Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

Authors:  Kamran Ghoreschi; Michael I Jesson; Xiong Li; Jamie L Lee; Sarbani Ghosh; Jason W Alsup; James D Warner; Masao Tanaka; Scott M Steward-Tharp; Massimo Gadina; Craig J Thomas; John C Minnerly; Chad E Storer; Timothy P LaBranche; Zaher A Radi; Martin E Dowty; Richard D Head; Debra M Meyer; Nandini Kishore; John J O'Shea
Journal:  J Immunol       Date:  2011-03-07       Impact factor: 5.422

8.  Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

Authors:  K A Papp; A Menter; B Strober; R G Langley; M Buonanno; R Wolk; P Gupta; S Krishnaswami; H Tan; J A Harness
Journal:  Br J Dermatol       Date:  2012-09       Impact factor: 9.302

9.  Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15.

Authors:  J A Johnston; C M Bacon; D S Finbloom; R C Rees; D Kaplan; K Shibuya; J R Ortaldo; S Gupta; Y Q Chen; J D Giri
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

10.  A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

Authors:  W C Ports; S Khan; S Lan; M Lamba; C Bolduc; R Bissonnette; K Papp
Journal:  Br J Dermatol       Date:  2013-07       Impact factor: 9.302
  10 in total
  49 in total

Review 1.  Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.

Authors:  Ralph M Trüeb; Maria Fernanda Reis Gavazzoni Dias
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  Two birds that exclude each other: the Renbök phenomenon.

Authors:  Paradi Mirmirani
Journal:  J Invest Dermatol       Date:  2014-11-28       Impact factor: 8.551

3.  Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment.

Authors:  Bo Young Kim; Hyun-Sook Kim
Journal:  Singapore Med J       Date:  2017-05       Impact factor: 1.858

4.  [Treatment of vitiligo].

Authors:  M Meurer; M Schild
Journal:  Hautarzt       Date:  2016-03       Impact factor: 0.751

5.  Recovery of nail dystrophy potential new therapeutic indication of tofacitinib.

Authors:  Jose A Jaller; Juan J Jaller; Antonio M Jaller; Juan J Jaller-Char; Sineida Berbert Ferreira; Rachel Ferreira; Morton Scheinberg
Journal:  Clin Rheumatol       Date:  2017-02-16       Impact factor: 2.980

Review 6.  [Systemic treatment of vitiligo : Balance and current developments].

Authors:  M Meurer; P Ceric-Dehdari
Journal:  Hautarzt       Date:  2017-11       Impact factor: 0.751

Review 7.  Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.

Authors:  A Sterkens; J Lambert; A Bervoets
Journal:  Clin Exp Med       Date:  2021-01-01       Impact factor: 3.984

8.  Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.

Authors:  Milène Kennedy Crispin; Justin M Ko; Brittany G Craiglow; Shufeng Li; Gautam Shankar; Jennifer R Urban; James C Chen; Jane E Cerise; Ali Jabbari; Mårten Cg Winge; M Peter Marinkovich; Angela M Christiano; Anthony E Oro; Brett A King
Journal:  JCI Insight       Date:  2016-09-22

9.  Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.

Authors:  Julian Mackay-Wiggan; Ali Jabbari; Nhan Nguyen; Jane E Cerise; Charlotte Clark; Grace Ulerio; Megan Furniss; Roger Vaughan; Angela M Christiano; Raphael Clynes
Journal:  JCI Insight       Date:  2016-09-22

Review 10.  Understanding autoimmunity of vitiligo and alopecia areata.

Authors:  Jillian F Rork; Mehdi Rashighi; John E Harris
Journal:  Curr Opin Pediatr       Date:  2016-08       Impact factor: 2.856
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.